EUVIMEDEUVIMED entdecken
Open Access

FGF21 reverses MASH through coordinated actions on the CNS and liver

Jesse P Rose, Donald A Morgan, Andrew I Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C Burgess, David K Meyerholz, Kamal Rahmouni, Matthew J Potthoff

Cell Metabolism · 2025-07 · 37 (7) · 1515-1529.e6

DOI: 10.1016/j.cmet.2025.04.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2025-07. Verfasst von Jesse P Rose und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA; Fraternal Order of Eagles Diabe…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Liver, Central Nervous System, Fatty Liver. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a growing public health burden with limited therapeutic options. Recent studies have revealed that fibroblast growth factor 21 (FGF21)-based analogs can significantly improve MASH, but the mechanisms for this effect are not well understood. Here, we demonstrate that the beneficial metabolic effects of FGF21 to reverse MASH are mediated through distinct mechanisms to independently lower hepatic triglyceride and cholesterol levels. Specifically, FGF21 signaling directly to glutamatergic neurons in the central nervous system (CNS) stimulates hepatic triglyceride reduction and reversal of fibrosis, whereas FGF21 signaling directly to hepatocytes is necessary and sufficient to reduce hepatic cholesterol levels in mice. Mechanistically, we show that FGF21 acts in the CNS to increase sympathetic nerve activity to the liver, which suppresses hepatic de novo lipogenesis. These results provide critical insights into a promising pharmacological target to treat MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsLiverCentral Nervous SystemFatty LiverAnimalsMiceMice, Inbred C57BLMaleTriglyceridesHepatocytesCholesterolLipogenesisSignal TransductionHumans

Stichwörter der Autor:innen

FGF21MASHMASLDbetaklothobrainhepatic innervationhepatokineliversympathetic nerve activity

Substanzen

Fibroblast Growth Factorsfibroblast growth factor 21TriglyceridesCholesterol

Autor:innen und Institutionen

  • Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA; Fraternal Order of Eagles Diabetes Research Center, University of Iowa Carver College of Medicine, Io…
  • Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046, USA.
  • Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIDDK NIH HHS
  • BLRD VA
  • NIAAA NIH HHS
  • US Department of Veterans Affairs
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Cystic Fibrosis Foundation

Zitieren

APA

Rose, J. P., Morgan, D. A., Sullivan, A. I., Fu, X., Inigo-Vollmer, M., Burgess, S. C., Meyerholz, D. K., Rahmouni, K., & Potthoff, M. J. (2025). FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metabolism, 37(7), 1515-1529.e6. https://doi.org/10.1016/j.cmet.2025.04.014

Vancouver

Rose JP, Morgan DA, Sullivan AI, Fu X, Inigo-Vollmer M, Burgess SC, et al. FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metabolism. 2025;37(7):1515-1529.e6. doi:10.1016/j.cmet.2025.04.014

BibTeX
@article{Rose2025,
  author = {Rose, Jesse P and Morgan, Donald A and Sullivan, Andrew I and Fu, Xiaorong and Inigo-Vollmer, Melissa and Burgess, Shawn C and Meyerholz, David K and Rahmouni, Kamal and Potthoff, Matthew J},
  title = {FGF21 reverses MASH through coordinated actions on the CNS and liver},
  journal = {Cell Metabolism},
  year = {2025},
  volume = {37},
  number = {7},
  pages = {1515--1529.e6},
  doi = {10.1016/j.cmet.2025.04.014}
}
Kostenlos starten →